Bolt Biotherapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BOLT research report →
Companywww.boltbio.com
Bolt Biotherapeutics, Inc. , a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages.
- CEO
- William Quinn
- IPO
- 2021
- Employees
- 52
- HQ
- Redwood City, CA, US
Price Chart
Valuation
- Market Cap
- $8.86M
- P/E
- -0.29
- P/S
- 1.36
- P/B
- 0.43
- EV/EBITDA
- -0.67
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 96.88%
- Op Margin
- -463.44%
- Net Margin
- -455.15%
- ROE
- -100.90%
- ROIC
- -69.02%
Growth & Income
- Revenue
- $7.70M · 0.07%
- Net Income
- $-33,376,000 · 47.12%
- EPS
- $-17.85 · -981.82%
- Op Income
- $-34,633,000
- FCF YoY
- 34.91%
Performance & Tape
- 52W High
- $9.24
- 52W Low
- $3.91
- 50D MA
- $4.65
- 200D MA
- $5.20
- Beta
- 1.10
- Avg Volume
- 23.84K
Get TickerSpark's AI analysis on BOLT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 28, 26 | Quinn William P. | other | 20,000 |
| Dec 5, 25 | Quinn William P. | buy | 125 |
| Jan 28, 26 | Yonehiro Grant | other | 10,000 |
| Jan 28, 26 | Nemec Sarah | other | 8,000 |
| Dec 5, 25 | Nemec Sarah | buy | 125 |
| Dec 12, 25 | Dupont Jakob | other | 2,500 |
| Dec 12, 25 | Dupont Jakob | other | 1,100 |
| Dec 12, 25 | Dupont Jakob | other | 1,000 |
| Dec 12, 25 | Dupont Jakob | other | 849 |
| Dec 12, 25 | Dupont Jakob | sell | 1,000 |
Our BOLT Coverage
We haven't published any research on BOLT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BOLT Report →